Price T Rowe Associates Inc. MD Purchases 6,966 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Price T Rowe Associates Inc. MD increased its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 51.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,565 shares of the company’s stock after acquiring an additional 6,966 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Zevra Therapeutics were worth $172,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its position in Zevra Therapeutics by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock valued at $23,554,000 after purchasing an additional 68,151 shares during the last quarter. Altium Capital Management LLC lifted its position in Zevra Therapeutics by 8.8% during the fourth quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock valued at $15,429,000 after purchasing an additional 150,000 shares during the last quarter. Geode Capital Management LLC lifted its position in Zevra Therapeutics by 13.8% during the fourth quarter. Geode Capital Management LLC now owns 1,188,120 shares of the company’s stock valued at $9,912,000 after purchasing an additional 144,256 shares during the last quarter. AIGH Capital Management LLC bought a new stake in Zevra Therapeutics during the fourth quarter valued at approximately $6,577,000. Finally, Retirement Planning Co of New England Inc. lifted its position in Zevra Therapeutics by 3.1% during the fourth quarter. Retirement Planning Co of New England Inc. now owns 514,832 shares of the company’s stock valued at $4,294,000 after purchasing an additional 15,327 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Stock Up 2.7%

Shares of NASDAQ ZVRA opened at $8.66 on Friday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76. The firm’s fifty day moving average is $7.54 and its 200 day moving average is $8.07. The company has a market cap of $473.52 million, a price-to-earnings ratio of -4.40 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. During the same period in the previous year, the firm earned ($0.40) earnings per share. On average, equities research analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Insider Buying and Selling

In other news, Director John B. Bode bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 19th. The shares were bought at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at $318,400. This represents a 33.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on ZVRA. Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Canaccord Genuity Group lifted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Thursday, March 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $22.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.